Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person The cardiovascular and other actions of the vasoconstricting...
| Class:Id | Summation:374239 |
|---|---|
| _displayName | The cardiovascular and other actions of the vasoconstricting... |
| _timestamp | 2008-08-29 12:53:13 |
| created | [InstanceEdit:374171] Jassal, Bijay, 2008-07-28 |
| modified | [InstanceEdit:374263] Jassal, Bijay, 2008-07-28 [InstanceEdit:375446] Jassal, Bijay, 2008-08-29 |
| text | The cardiovascular and other actions of the vasoconstricting peptide angiotensin II are mediated by the type 1 and type 2 angiotensin II receptors (AT1 and AT2), which are seven transmembrane glycoproteins with 30% sequence similarity. AT1 receptors (Bergsma DJ et al, 1992) couple to G(q/11), and signal through phospholipases A, C, D, inositol phosphates, calcium channels, and a variety of serine/threonine and tyrosine kinases. The AT2 receptor (Tsuzuki S et al, 1994) is expressed mainly during fetal development. It is much less abundant in adult tissues and is up-regulated in pathological conditions. Its signaling pathways include serine and tyrosine phosphatases, phospholipase A2, nitric oxide, and cyclic guanosine monophosphate. The AT2 receptor counteracts several of the growth responses initiated by the AT1 and growth factor receptors. |
| (summation) | [Reaction:374173] AGT(25-32) binds to AGTR1 [Homo sapiens] [Reaction:9615348] AGT(25-32) binds to AGTR2 [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by The cardiovascular and other actions of the vasoconstricting... (374239)
